Shots:
Recently, QurAlis signed an exclusive license agreement with Lilly for QRL-204 for patients with ALS and FTD
Under the terms of the agreement, QurAlis granted Lilly an exclusive worldwide license to develop and commercialize QRL-204 and other UNC13A targeting compounds.
QurAlis received an up front payment of $45M plus an additional equity investment. The company is…
